IQVIA

685 articles with IQVIA

• IQVIA’s eCOA Solution Receives 2020 Fierce Innovation Award

  9/14/2020

  IQVIA™ (NYSE: IQV) today announced that its electronic Clinical Outcome Assessment (eCOA) solution, an advanced-study build and execution platform that optimizes real-time, direct-from-patient data collection, has been selected as the winner of the Fierce Innovation Awards – Life Sciences Edition 2020 in the Digital Health Solutions category. The Fierce Innovation Awards is a peer-revie

• IQVIA’s Nancy Dreyer and Deepa Desai Honored with 2020 PharmaVOICE Awards

  8/5/2020

  IQVIA™ announced that Nancy Dreyer, chief scientific officer and senior vice president, Real World Solutions, has been awarded PharmaVOICE magazine’s Red Jacket honor after she was recognized multiple times as a PharmaVOICE 100.

• Drug Prices Have Become More Affordable to Most Patients, says U.S. Medicine Spending Study from the IQVIA Institute for Human Data Science

  8/4/2020

  The average amount paid out-of-pocket per prescription remains steady at $10.67, unchanged from 2018 and up only $0.33 since 2014, as high levels of generic drug use and greater use of manufacturer coupons offset higher costs

• IQVIA Launches OCE Optimizer to Help Intelligently Plan HCP Engagements and Maximize Commercial Effectiveness

  7/29/2020

  IQVIA™ (NYSE: IQV) today introduced OCE Optimizer , an innovative solution that empowers life sciences companies to plan and refine marketing engagements with healthcare providers (HCPs) on demand. OCE Optimizer extends IQVIA’s Orchestrated Customer Engagement solution by intelligently allocating

• IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance

  7/22/2020

  IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance Second quarter revenue $2,521 million and Adjusted EBITDA $483 million GAAP Diluted Earnings per Share $(0.12); Adjusted Diluted Earnings per Share $1.18 R&D Solutions quarterly net book-to-bill ratio 1.64x including pass throughs and 1.60x excluding pass throughs; contracted backlog including pass throughs grew 13.5 percent year-over-year to $20.5 billion

• IQVIA and JDRF Collaborate to Improve Understanding of Type 1 Diabetes Using Real World Data

  7/20/2020

  IQVIA™ (NYSE: IQV) today announced it is joining forces with JDRF , the leading global organization funding type 1 diabetes (T1D) research, to use non-identified patient-level, real world data and analytics to address unmet n

• IQVIA Collaborates with LMC Manna Research to Launch the Largest Clinical Investigation Site in Canada

  7/2/2020

  IQVIA™ (NYSE: IQV) today announced its strategic alliance with LMC Manna Research, the largest network of fully owned and integrated clinical research sites in Canada, to launch IQVIA’s first Prime Site in Canada. This adds to our network of more than 980 Prime and Partner clinical sites globally, which are sites with special designation assuring pharmaceutical and biotech companies their

• IQVIA Announces Pricing of Offering of Senior Notes - June 10, 2020

  6/10/2020

  IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., priced an offering of €711,000,000 in aggregate principal amount of senior notes due 2028.

• IQVIA Launches the First Solution to Address the Unique Business and Compliance Needs of Healthcare Professionals as Part of Its OCE Suite

  5/21/2020

  IQVIA™ (NYSE: IQV) today announced the launch of HCP/O Engagement Management, the industry’s first end-to-end, orchestrated healthcare professional/organization (HCP/O) solution that enables the planning, management, contracting, and payment of HCP/Os globally. “IQVIA Technologies is excited to launch its latest offering, HCP/O Engagement Management. As part of IQVIA’s Orchestrated C

• IQVIA Collaborates with Australian Medical Research Institute on COVID-19 Study to Support Frontline Healthcare Workers

  5/20/2020

  Randomized, double-blind clinical study will test Hydroxychloroquine as a prophylactic treatment to prevent high-risk healthcare workers from contracting COVID-19 DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--( BUSINESS WIRE )-- IQVIA™ (NYSE: IQV) today announced that the Walter and Eliza Hall Institute of Medical Research , a leading biomedical research organization in Australia, has selected IQVIA to manage COVID SHIELD, a Phase II/III randomize

• 

  Biopharma Update on the Novel Coronavirus: May 18

  5/18/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.

• IQVIA Joins UK Government Collaboration to Provide Single Research Platform to Speed Development of New COVID-19 Treatments

  4/29/2020

  IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, has joined the ACCORD-2 collaboration, which will fast-track development of new treatments for COVID-19. IQVIA will provide a single research platform across the United Kingdom to facilitate multiple clinical trials regardless of sponsor.

• IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance

  4/28/2020

  IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, reported financial results for the quarter ended March 31, 2020.

• IQVIA Launches Broad, Open COVID-19 Registry Platform to Advance Understanding, Collaboration, and Research

  4/7/2020

  IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced the launch of its COVID Active Research Experience (CARE) Project at helpstopcovid19.com . The IQVIA CARE Project is an opt-in registry available to anyone – to advance understanding of COVID-19 through shared information about disease prevalence, symptom progression, and treatment outcomes. “In this unprecedented

• IQVIA Launches First Technology-Enabled COVID-19 Trial Matching Solution within the U.S. to Accelerate Treatment and Vaccine Development

  4/7/2020

  IQVIA™, a leader in Human Data Science, announced its new technology-enabled COVID-19 Trial Matching Tool at c19trials.com, which is one of the world’s first online platforms that matches individuals with specific COVID-19 studies to accelerate clinical research projects.

• IQVIA Provides Update on Business Conditions in Light of COVID-19 and Provides Revised First-quarter 2020 Guidance; IQVIA will announce first-quarter results and update full-year 2020 guidance on April 28, 2020

  4/3/2020

  IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, updated its first-quarter 2020 guidance and provided a business update in light of the global COVID-19 crisis.

• Apttus and HighPoint, an IQVIA Company, Expand Quote-to-Cash System Integrator (SI) Partnership Across the Globe

  3/9/2020

  Apttus and HighPoint, an IQVIA company, Have Partnered To Bring Digital Transformation To Tech Projects Across the Healthcare and Life Sciences Industry

• IQVIA Launches Avacare Clinical Research Network to Increase Patients’ Clinical and Research Options

  2/20/2020

  Feb. 20, 2020 13:49 UTC DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--( BUSINESS WIRE )-- IQVIA™ (NYSE: IQV), a leader in human data science, today announced the launch of Avacare Clinical Research Network™, a technology-based global site network that opens opportunities for more clinical trials at experienced clinical and research sites. Avacare’s unique analytical tools help sites in Avacare’s network match patients to clinical trials faster and more effectively. “We b

• CIBMTR® Announces Real World Data Effort to Accelerate Breakthroughs that Transform Patient Experiences in Cellular Therapy with IQVIA

  2/19/2020

  The CIBMTR® announced the selection of IQVIA as it seeks to expand the value real world data can bring to patients, through systematic investigation to generate real world evidence.

• IQVIA Announces Repurchase of Common Stock - Feb. 13, 2020

  2/13/2020

  IQVIA Holdings Inc. announced that it has agreed to purchase an aggregate of 1,000,000 shares of its common stock in a private transaction from certain of its existing stockholders.